Joseph McEvoy, MD
Psychiatry · Augusta, GANPI 1962586859
Payments from drug & device makers
Across 575 payments — averaging $1097.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$315K
- Teva Pharmaceuticals USA, Inc.$91K
- Biogen$74K
- Boehringer Ingelheim$72K
- Neurocrine Biosciences, Inc.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$20K
- plus $13K from 14 others
Across 1 payment — averaging $4998.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$5K
What the payments were for
- Consulting fees$16,37545%
- Speaking & faculty fees$10,45029%
- Travel & lodging$3,95711%
- Food & beverage$5,66616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 228 | $315,241 |
| Teva Pharmaceuticals USA, Inc. | 179 | $91,256 |
| Biogen | 5 | $73,785 |
| Boehringer Ingelheim | 24 | $72,204 |
| Neurocrine Biosciences, Inc. | 59 | $45,888 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $19,884 |
| Boehringer Ingelheim RCV GmbH & Co KG | 2 | $3,884 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $2,649 |
| Sunovion Pharmaceuticals Inc. | 18 | $1,557 |
| Eli Lilly | 1 | $1,456 |
| Merck | 1 | $1,053 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $640 |
| AbbVie(2 entities) | 9 | $491 |
| Otsuka America Pharmaceutical, Inc. | 9 | $417 |
| Janssen Scientific Affairs, LLC | 6 | $286 |
| Johnson & Johnson | 10 | $186 |
| Livanova USA, Inc. | 1 | $132 |
| Lundbeck LLC | 2 | $105 |
| Axsome Therapeutics, Inc. | 1 | $86 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$19,486
- ARISTADA$5,709
- ARISTADA INITIO$1,427
- VRAYLAR$326
- ABILIFY MAINTENA$218
- VNS Therapy Symmetry Model 8103 Generator$132
How this compares
$631,229 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 48 | $92,374 |
| Clozapine | 100 | $9,490 |
| Aripiprazole | 18 | $1,939 |
| Olanzapine | 80 | $1,144 |
| Divalproex Sodium ErDivalproex Sodium | 17 | $989 |
| Gabapentin | 91 | $740 |
| Glycopyrrolate | 25 | $623 |
| Desmopressin Acetate | 18 | $617 |
| Risperidone | 37 | $579 |
| Oxcarbazepine | 12 | $531 |
| Clonazepam | 69 | $390 |
| Lamotrigine | 63 | $390 |
| Quetiapine Fumarate | 17 | $378 |
| Duloxetine Hcl | 22 | $356 |
| Metformin Hcl ErMetformin Hcl | 47 | $325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $186 | $92,37448 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Augusta
- Marshall BedderAugusta$182K
- Peter RosenquistAugusta$96K
- William McCallAugusta$72K
- Robert RiesenbergAtlanta$51.1M
- Saundra Maass-RobinsonAtlanta$11.1M
- David PurselleAtlanta$7.4M
- Maria JohnsonDecatur$5.4M
- Bethany DavisAtlanta$4.4M
- Michael BanovMarietta$4.2M
- Michael MobleySavannah$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.